Quality of life and local treatment of oligometastatic prostate cancer
Prof Claude Abbou - Clinique de l'Alma, Paris, France
Quality of life and local treatment of oligometastatic prostate cancer ( Prof Claude Abbou - Clinique de l'Alma, Paris, France )
8 May 2019
Challenges in the treatment of upper urinary tract tumours
Prof Amr Emara - Basingstoke and North Hampshire Hospital, Basingstoke, UK
Challenges in the treatment of upper urinary tract tumours ( Prof Amr Emara - Basingstoke and North Hampshire Hospital, Basingstoke, UK )
8 May 2019
PARP inhibitors and their side effects in solid tumour therapy
Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA
PARP inhibitors and their side effects in solid tumour therapy ( Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA )
8 May 2019
Challenges to Jordanian Muslim men with prostate cancer
Abdulmalik Hasanain - Victoria University of Wellington, Wellington, New Zealand
Challenges to Jordanian Muslim men with prostate cancer ( Abdulmalik Hasanain - Victoria University of Wellington, Wellington, New Zealand )
8 May 2019
5' UTR mutations in prostate cancer
Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA
5' UTR mutations in prostate cancer ( Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA )
15 Apr 2019
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in...
Dr James Gulley - National Cancer Institute, Bethesda, USA
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )
15 Apr 2019
Risk factors for prostate cancer in men of African descent
Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria
Risk factors for prostate cancer in men of African descent ( Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria )
15 Apr 2019
GU Debates 2019: Changing treatment paradigms for hormone-naïve and castration-r...
Dr Eleni Efstathiou, Prof Peter Goebell, Prof Joaquim Bellmunt, Prof Thomas Steu...
GU Debates 2019: Changing treatment paradigms for hormone-naïve and castration-resistant prostate cancer (1/2) ( Dr Eleni Efstathiou, Prof Peter Goebell, Prof Joaquim Bellmunt, Prof Thomas Steuber )
10 Apr 2019
GU Debates 2019: Practice-changing developments in urothelial cancer (2/2)
GU Debates 2019: Practice-changing developments in urothelial cancer (2/2) (  )
9 Apr 2019
ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate ...
Prof Karim Fizazi, Dr Eleni Efstathiou
ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate cancer ( Prof Karim Fizazi, Dr Eleni Efstathiou )
15 Mar 2019
Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma
Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK
Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma ( Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK )
19 Feb 2019
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clea...
Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma ( Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )
19 Feb 2019